www.uhasselt.be
DSpace

Document Server@UHasselt >
Research >
Research publications >

Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/24192

Title: RISK stratification in paediatric Crohn's disease
Authors: Arijs, Ingrid
Cleynen, Isabelle
Issue Date: 2017
Publisher: ELSEVIER SCIENCE INC
Citation: LANCET, 389(10080), p. 1672-1674
Abstract: Background Stricturing and penetrating complications account for substantial morbidity and health-care costs in paediatric and adult onset Crohn’s disease. Validated models to predict risk for complications are not available, and the effect of treatment on risk is unknown. Methods We did a prospective inception cohort study of paediatric patients with newly diagnosed Crohn’s disease at 28 sites in the USA and Canada. Genotypes, antimicrobial serologies, ileal gene expression, and ileal, rectal, and faecal microbiota were assessed. A competing-risk model for disease complications was derived and validated in independent groups. Propensity-score matching tested the effect of anti-tumour necrosis factor α (TNFα) therapy exposure within 90 days of diagnosis on complication risk. Findings Between Nov 1, 2008, and June 30, 2012, we enrolled 913 patients, 78 (9%) of whom experienced Crohn’s disease complications. The validated competing-risk model included age, race, disease location, and antimicrobial serologies and provided a sensitivity of 66% (95% CI 51–82) and specificity of 63% (55–71), with a negative predictive value of 95% (94–97). Patients who received early anti-TNFα therapy were less likely to have penetrating complications (hazard ratio [HR] 0·30, 95% CI 0·10–0·89; p=0·0296) but not stricturing complication (1·13, 0·51–2·51; 0·76) than were those who did not receive early anti-TNFα therapy. Ruminococcus was implicated in stricturing complications and Veillonella in penetrating complications. Ileal genes controlling extracellular matrix production were upregulated at diagnosis, and this gene signature was associated with stricturing in the risk model (HR 1·70, 95% CI 1·12–2·57; p=0·0120). When this gene signature was included, the model’s specificity improved to 71%. Interpretation Our findings support the usefulness of risk stratification of paediatric patients with Crohn’s disease at diagnosis, and selection of anti-TNFα therapy.
Notes: [Arijs, Ingrid] Hasselt Univ, Fac Med & Life Sci, Campus Diepenbeek,Agoralaan Gebouw D, B-3590 Diepenbeek, Hasselt, Belgium. [Arijs, Ingrid] Jessa Hosp, Hasselt, Belgium. [Arijs, Ingrid] Katholieke Univ Leuven, Translat Res Gastrointestinal Disorders TARGID, Dept Clin & Expt Med, Leuven, Belgium. [Cleynen, Isabelle] Katholieke Univ Leuven, Dept Human Genet, Lab Complex Genet, Leuven, Belgium.
URI: http://hdl.handle.net/1942/24192
DOI: 10.1016/S0140-6736(17)30634-7
ISI #: 000400151000005
ISSN: 0140-6736
Category: A2
Type: Journal Contribution
Appears in Collections: Research publications

Files in This Item:

Description SizeFormat
Published version393.05 kBAdobe PDF

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.